Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency is a very rare inherited metabolic disorder caused by biallelic variants in the MCEE gene. The defect reduces the conversion of certain protein and fat breakdown products, leading to the accumulation of methylmalonic acid in blood, urine, and cerebrospinal fluid.
Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency
Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency belongs to the group of isolated methylmalonic acidemias. It is caused by a partial or marked decrease in the activity of the enzyme methylmalonyl-CoA epimerase, encoded by the MCEE gene.
Methylmalonyl-CoA epimerase participates in the pathway that processes amino acids such as isoleucine, valine, threonine, and methionine, as well as odd-chain fatty acids and other propionate-derived compounds. When the enzyme does not function properly, normal conversion to succinyl-CoA is interrupted, and methylmalonic acid is elevated.
The disease follows an autosomal recessive pattern: to be affected, a person typically inherits an altered copy of the gene from each parent. Clinical presentation is highly variable, ranging from mild biochemical elevations or absence of symptoms to severe metabolic crises. It is considered an ultra-rare cause of persistent methylmalonic acidemia.
Symptoms
The clinical spectrum is broad and can range from asymptomatic cases to severe metabolic acidosis. When symptoms appear, they usually do so in childhood or during episodes of decompensation triggered by infections, fasting, or increased catabolism. Crises can include vomiting, dehydration, lethargy, hypotonia, ataxia, seizures, or coma. In some patients, developmental delay, intellectual disability, spasticity, movement disorders, growth difficulties, and other neurological problems have been described.
Disease management
Management aims to avoid metabolic decompensations and reduce the accumulation of toxic metabolites. It may include monitoring by a specialized metabolic team, individualized control of proteins and precursor amino acids, adequate caloric intake, avoidance of prolonged fasting, and early treatment of infections or stressful situations. L-carnitine and an emergency plan for acute crises are indicated in certain patients; vitamin B12 is usually not effective in UCD deficiency.
Genes analyzed
Bibliography
Fraser JL, Venditti CP. Methylmalonic and propionic acidemias: clinical management update. Curr Opin Pediatr. 2016 Dec;28(6):682-693.
Manoli I, Sloan JL, Venditti CP. Isolated Methylmalonic Acidemia. 2005 Aug 16 [updated 2022 Sep 8]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
